Focused On-demand Library for Glutamate receptor ionotropic, NMDA 2C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14957

UPID:

NMDE3_HUMAN

Alternative names:

Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C

Alternative UPACC:

Q14957; B2RTT1

Background:

The Glutamate receptor ionotropic, NMDA 2C, also known as Glutamate [NMDA] receptor subunit epsilon-3 and N-methyl D-aspartate receptor subtype 2C, plays a pivotal role in neural communication. It is a component of NMDA receptor complexes, crucial for high calcium permeability and voltage-dependent sensitivity to magnesium. Activation of this receptor is essential for synaptic plasticity, contributing to learning and memory by regulating excitatory and inhibitory activities in the prefrontal cortex.

Therapeutic significance:

Understanding the role of Glutamate receptor ionotropic, NMDA 2C could open doors to potential therapeutic strategies.